枸橼酸抗凝显著延长CRRT滤器寿命:一项单中心真实世界队列研究OA
Citrate Anticoagulation Significantly Prolongs Filter Life in Continuous Renal Replacement Therapy:a Single-center real-world Cohort Study
目的 探讨不同抗凝策略对重症监护病房(intensive care unit,ICU)连续性肾脏替代治疗(continuous renal replacement therapy,CRRT)滤器寿命的影响,并分析影响滤器凝血的相关因素.方法 采用回顾性队列研究方法,收集2025年7月至2025年8月本院综合ICU内所有符合纳入标准的CRRT患者资料,共纳入187例患者的首次CRRT治疗数据.记录患者人口学特征、急性生理与慢性健康评估Ⅱ(acute physiology and chronic health evaluation Ⅱ,APACHEⅡ)评分、序贯器官衰竭估计(sequential organ failure assessment,SOFA)评分、CRRT参数、抗凝方法、凝血功能指标(血小板计数、凝血酶原时间、活化部分凝血活酶时间、国际标准化比值)及治疗终止原因.主要结局指标为滤器生存时间,采用Kaplan-Meier法绘制生存曲线,Log-rank检验进行比较,并运用Cox比例风险回归模型分析影响滤器凝血风险的独立因素.结果 187例患者中,枸橼酸、普通肝素和甲磺酸萘莫司他抗凝分别占51.34%、29.41%和19.25%.63例(33.69%)因滤器凝血终止治疗,是治疗中断的首要原因.多因素Cox回归分析显示,与肝素抗凝相比,枸橼酸抗凝可显著降低滤器凝血风险[风险比(hazard ratio,HR)=0.52,95%置信区间(confidence interval,CI):0.31~0.88,P=0.015];血流速度>150 mL/min为保护因素(HR=0.65,95%CI:0.43~0.98,P=0.039);而机械通气是滤器凝血的风险因素(HR=2.15,95%CI:1.16~3.99,P=0.015).凝血功能指标与滤器凝血风险无显著相关性(P>0.05).Kaplan-Meier生存分析显示,枸橼酸组、肝素组和甲磺酸萘莫司他组滤器中位生存时间分别为38.5、18.0和26.0 h,差异有统计学意义(Log-rank P<0.001).结论 在CRRT中,区域性枸橼酸抗凝能有效延长滤器寿命,降低凝血风险,建议作为首选抗凝策略.同时,在患者耐受前提下维持较高血流速度(>150 mL/min),并对机械通气等高风险患者实施个体化抗凝管理,有助于优化CRRT疗效.
Objective To investigate the effects of different anticoagulation strategies on filter life during continu-ous renal replacement therapy(CRRT)in the intensive care unit(ICU)and to analyze the factors associated with filter clot-ting.Methods A retrospective cohort study was conducted.Data from 187 patients receiving their first CRRT treatment in the general ICU of a tertiary hospital from July to August 2025 were collected.Patient demographics,illness severity scores(APACHE II,SOFA),CRRT parameters,anticoagulation methods,coagulation indicators(platelet count,prothrombin time,activated partial thromboplastin time,international normalized ratio),and reasons for treatment discontinuation were recorded.The primary outcome was filter survival time,analyzed using Kaplan-Meier method with Log-rank test.A Cox proportional hazards regression model was used to identify inde-pendent factors affecting filter clotting risk.Results Among the 187 patients,citrate anticoagulation was used in 51.34%,unfractionated heparin in 29.41%,and nafamostat mesilate in 19.25%.Sixty-three patients(33.69%)were terminated due to filter clotting,which was the leading cause of treatment interruption.Multivariable Cox regression analysis showed that compared with heparin anticoagulation,citrate anticoagulation significantly reduced the risk of filter clotting[hazard ratio(HR)=0.52,95%confidence interval(CI):0.31~0.88,P=0.015].A blood flow rate>150 mL/min was a protective factor(HR=0.65,95%CI:0.43~0.98,P=0.039),while mechanical ventilation was a risk factor for filter clotting(HR=2.15,95%CI:1.16~3.99,P=0.015).Coagulation pa-rameters showed no significant association with the risk of filter clotting(P>0.05).Kaplan-Meier survival analysis showed that the median filter survival times for the citrate,heparin,and nafamostat groups were 38.5 h,18.0 h,and 26.0 h,respective-ly,with a statistically significant difference(Log-rank P<0.001).Conclusions Regional citrate anticoagulation effective-ly prolongs filter life and reduces clotting risk in CRRT,and should be considered as the preferred anticoagulation strategy.Maintaining a blood flow rate>150 mL/min helps reduce the clotting risk.Patients on mechanical ventilation are at high risk for filter clotting and require individualized and intensified anticoagulation management.
欧庆;何丹;史秀英;颜文娟;张冷祯;刘亚楠;魏红云
南方医科大学南方医院重症医学科,广州 510515南方医科大学南方医院重症医学科,广州 510515南方医科大学南方医院重症医学科,广州 510515南方医科大学南方医院重症医学科,广州 510515南方医科大学南方医院重症医学科,广州 510515南方医科大学南方医院重症医学科,广州 510515南方医科大学南方医院重症医学科,广州 510515
连续性肾脏替代治疗抗凝枸橼酸盐
continuous renal replacement therapyanticoagulationcitrate
《中华灾害救援医学》 2026 (2)
152-157,6
南方医科大学护理科研专项基金(Y2025015)广东省护理学会、广东省岭南南丁格尔护理研究院科研基金(GDSHLXHYJYB202640)
评论